BRCA1 and cancer: In addition, 39 of 79 (49.4%) patients with BRCA1/2 mutant cancers developed RDR when receiving PARP inhibitor monotherapy, in contrast to 7 of 34 (20.6%) patients with unknown or wildtype BRCA1/2 status (p=0.004).